Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Filing marks first protein-based vaccine submitted to MHRA for authorization
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
